Scholarlink

<p>Dedifferentiated liposarcoma (DDLPS) is a rare and aggressive subtype of liposarcoma, driven by a core transcriptional regulatory circuitry (CRC) that sustains tumor proliferation. This malignancy poses considerable clinical challenges, marked by high postoperative recurrence and metastatic potential, alongside a lack of effective targeted therapies. In this study, we establish that KPT-330 (Selinexor), a selective inhibitor of exportin 1 (XPO1), effectively compromises DDLPS cell viability by perturbing CRC homeostasis. Mechanistically, we demonstrate that KPT-330 attenuates the cellular translation machinery in a biphasic manner: initially, it disrupts translation initiation by suppressing eukaryotic translation initiation factor 4E phosphorylation and eukaryotic translation initiation factor 4 F complex assembly; subsequently, it impedes translation elongation by inhibiting the nuclear export of ribosomal large subunit proteins. Furthermore, we identify a synergistic antitumor effect between KPT-330 and translation inhibitors, including everolimus and homoharringtonine. Notably, the disruptive impact of KPT-330 on CRC homeostasis extends to other cancer cell lineages, underscoring its broad mechanistic relevance. Collectively, our findings elucidate a novel mechanism through which KPT-330 destabilizes CRC via translational dysregulation and highlight its potential therapeutic utility in combination regimens for DDLPS.</p><p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

XPO1 inhibitor KPT-330 disrupts the core transcriptional regulatory circuitry of dedifferentiated liposarcoma by modulating the translation process

  • 期刊论文

  • 发表日期：

    2026年4月16日

查看全文
  • Xiaorui Fan,
  • Ying Zhang,
  • Zhengming Yang,
  • Tuan Zea Tan,
  • Xingze Huang,
  • Suya Zheng,
  • Jiyang Liu,
  • Long Xie,
  • Ting Tao,
  • Victor Kwanmin Lee,
  • Chao Yu,
  • H. Phillip Koeffler,
  • Ye Chen,
  • Liang Xu

摘要

Dedifferentiated liposarcoma (DDLPS) is a rare and aggressive subtype of liposarcoma, driven by a core transcriptional regulatory circuitry (CRC) that sustains tumor proliferation. This malignancy poses considerable clinical challenges, marked by high postoperative recurrence and metastatic potential, alongside a lack of effective targeted therapies. In this study, we establish that KPT-330 (Selinexor), a selective inhibitor of exportin 1 (XPO1), effectively compromises DDLPS cell viability by perturbing CRC homeostasis. Mechanistically, we demonstrate that KPT-330 attenuates the cellular translation machinery in a biphasic manner: initially, it disrupts translation initiation by suppressing eukaryotic translation initiation factor 4E phosphorylation and eukaryotic translation initiation factor 4 F complex assembly; subsequently, it impedes translation elongation by inhibiting the nuclear export of ribosomal large subunit proteins. Furthermore, we identify a synergistic antitumor effect between KPT-330 and translation inhibitors, including everolimus and homoharringtonine. Notably, the disruptive impact of KPT-330 on CRC homeostasis extends to other cancer cell lineages, underscoring its broad mechanistic relevance. Collectively, our findings elucidate a novel mechanism through which KPT-330 destabilizes CRC via translational dysregulation and highlight its potential therapeutic utility in combination regimens for DDLPS.